Tyra Biosciences, Inc. (TYRA) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth No data; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth Win.
14/33
2.1 / 5 stars
All 33 Win/Lose results and 87 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 6 wins, 2 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseTYRA / S&P -16.61% / 15.20% |
No dataTYRA / S&P / 15.00% |
LoseTYRA / S&P 34.27% / 50.40% |
| 2026-Q12/2 |
WinTYRA / S&P 45.68% / -4.33% |
No dataTYRA / S&P / 11.30% |
WinTYRA / S&P 33.13% / 27.70% |
| 2025-Q42/2 |
WinTYRA / S&P 87.92% / 2.65% |
No dataTYRA / S&P / 9.00% |
WinTYRA / S&P 32.45% / 13.40% |
| 2025-Q32/2 |
WinTYRA / S&P 46.19% / 8.12% |
No dataTYRA / S&P / 4.61% |
WinTYRA / S&P 16.15% / 13.45% |
| 2025-Q20/2 |
LoseTYRA / S&P 2.90% / 10.94% |
No dataTYRA / S&P / 4.83% |
LoseTYRA / S&P 5.33% / 10.63% |
| 2025-Q10/2 |
LoseTYRA / S&P -33.09% / -4.27% |
No dataTYRA / S&P / 4.98% |
LoseTYRA / S&P -2.98% / 10.57% |
| 2024-Q40/2 |
LoseTYRA / S&P -40.88% / 2.41% |
No dataTYRA / S&P / 5.25% |
LoseTYRA / S&P -6.21% / 6.15% |
| 2024-Q32/2 |
WinTYRA / S&P 47.03% / 5.89% |
No dataTYRA / S&P / 5.89% |
WinTYRA / S&P 16.67% / 6.11% |
| 2024-Q21/2 |
LoseTYRA / S&P -2.50% / 4.28% |
No dataTYRA / S&P / 5.38% |
WinTYRA / S&P 42.02% / 5.12% |
| 2024-Q12/2 |
WinTYRA / S&P 18.41% / 10.56% |
No dataTYRA / S&P / 5.71% |
WinTYRA / S&P 35.48% / 5.59% |
| 2023-Q41/2 |
LoseTYRA / S&P 0.58% / 11.69% |
No dataTYRA / S&P / 6.81% |
WinTYRA / S&P 21.97% / 7.78% |
| 2023-Q30/2 |
LoseTYRA / S&P -19.14% / -3.27% |
No dataTYRA / S&P / 7.52% |
LoseTYRA / S&P -297.14% / -5.03% |
| 2023-Q20/2 |
LoseTYRA / S&P 5.97% / 8.74% |
No dataTYRA / S&P / 9.50% |
LoseTYRA / S&P -525.00% / -8.57% |
| 2023-Q11/2 |
WinTYRA / S&P 111.45% / 7.50% |
No dataTYRA / S&P / 10.77% |
LoseTYRA / S&P -30.73% / -15.69% |
| 2022-Q40/1 |
LoseTYRA / S&P -13.54% / 7.56% |
No dataTYRA / S&P / 11.88% |
No dataTYRA / S&P / -17.99% |
| 2022-Q31/1 |
WinTYRA / S&P 22.94% / -4.88% |
No dataTYRA / S&P / 13.47% |
No dataTYRA / S&P / -1.41% |
| 2022-Q20/1 |
LoseTYRA / S&P -33.18% / -16.10% |
No dataTYRA / S&P / 13.71% |
No dataTYRA / S&P / 11.04% |
| 2022-Q10/1 |
LoseTYRA / S&P -23.95% / -4.60% |
No dataTYRA / S&P / 15.97% |
No dataTYRA / S&P / 42.23% |
| 2021-Q40/1 |
LoseTYRA / S&P -20.01% / 11.03% |
No dataTYRA / S&P / 15.00% |
No dataTYRA / S&P / 96.40% |
| 2021-Q30/0 |
No dataTYRA / S&P / 0.58% |
No dataTYRA / S&P / 10.77% |
No dataTYRA / S&P / 69.42% |
| 2021-Q20/0 |
No dataTYRA / S&P / 8.55% |
No dataTYRA / S&P / 6.58% |
No dataTYRA / S&P / 51.81% |
| 2021-Q10/0 |
No dataTYRA / S&P / 6.17% |
No dataTYRA / S&P / -1.06% |
No dataTYRA / S&P / 7.39% |
| 2020-Q40/0 |
No dataTYRA / S&P / 12.15% |
No dataTYRA / S&P / -3.72% |
No dataTYRA / S&P / -33.42% |
| 2020-Q30/0 |
No dataTYRA / S&P / 8.93% |
No dataTYRA / S&P / -2.04% |
No dataTYRA / S&P / -27.10% |
| 2020-Q20/0 |
No dataTYRA / S&P / 20.54% |
No dataTYRA / S&P / -0.46% |
No dataTYRA / S&P / -27.11% |
| 2020-Q10/0 |
No dataTYRA / S&P / -19.60% |
No dataTYRA / S&P / 3.47% |
No dataTYRA / S&P / -14.75% |
| 2019-Q40/0 |
No dataTYRA / S&P / 9.07% |
No dataTYRA / S&P / 5.36% |
No dataTYRA / S&P / 2.99% |
| 2019-Q30/0 |
No dataTYRA / S&P / 1.70% |
No dataTYRA / S&P / 5.02% |
No dataTYRA / S&P / 0.21% |
| 2019-Q20/0 |
No dataTYRA / S&P / 4.30% |
No dataTYRA / S&P / 6.64% |
No dataTYRA / S&P / 8.65% |
| 2019-Q10/0 |
No dataTYRA / S&P / 13.65% |
No dataTYRA / S&P / 8.12% |
No dataTYRA / S&P / 14.29% |
| 2018-Q40/0 |
No dataTYRA / S&P / -13.52% |
No dataTYRA / S&P / 9.05% |
No dataTYRA / S&P / 18.23% |
| 2018-Q30/0 |
No dataTYRA / S&P / 7.71% |
No dataTYRA / S&P / 10.21% |
No dataTYRA / S&P / 19.06% |
| 2018-Q20/0 |
No dataTYRA / S&P / 3.43% |
No dataTYRA / S&P / 9.03% |
No dataTYRA / S&P / 14.46% |
| 2018-Q10/0 |
No dataTYRA / S&P / -0.76% |
No dataTYRA / S&P / 7.68% |
No dataTYRA / S&P / 12.46% |
| 2017-Q40/0 |
No dataTYRA / S&P / 6.64% |
No dataTYRA / S&P / 7.03% |
No dataTYRA / S&P / 13.82% |
| 2017-Q30/0 |
No dataTYRA / S&P / 4.48% |
No dataTYRA / S&P / 5.68% |
No dataTYRA / S&P / 17.57% |
| 2017-Q20/0 |
No dataTYRA / S&P / 3.09% |
No dataTYRA / S&P / 4.83% |
No dataTYRA / S&P / 17.74% |
| 2017-Q10/0 |
No dataTYRA / S&P / 6.07% |
No dataTYRA / S&P / 3.67% |
No dataTYRA / S&P / 13.32% |
| 2016-Q40/0 |
No dataTYRA / S&P / 3.82% |
No dataTYRA / S&P / 2.09% |
No dataTYRA / S&P / 7.05% |
| 2016-Q30/0 |
No dataTYRA / S&P / 3.85% |
No dataTYRA / S&P / 0.20% |
No dataTYRA / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | TYRA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 106.24% | 20.78% |
| Annualized return | 106.24% | 20.78% |
5Y · 2021-09-15 to 2026-08-27
| Metric | TYRA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 0.50% | 83.14% |
| Annualized return | 0.10% | 12.86% |
10Y · 2021-09-15 to 2026-08-27
| Metric | TYRA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 0.50% | 319.30% |
| Annualized return | 0.05% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |